Hubungan Ekspresi LMP-1 dengan Overall Survival Pasien Diffuse Large B-Cell Lymphoma di RSUP Dr Kariadi Semarang
(1) Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia
(2) Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia
(3) Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia
(4) Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia
(5) Fakultas Kedokteran Universitas Diponegoro, Semarang, Indonesia
(*) Corresponding Author
Abstract
Latar Belakang: Latent membrane protein 1 (LMP1) merupakan onkoprotein abnormal yang paling utama ditemukan pada infeksi virus Epstein-Barr (EBV). LMP1 sering terekspresi pada berbagai keganasan terkait EBV, salah satunya adalah diffuse large B cell lymphoma (DLBCL). Beberapa literatur telah menjelaskan keterlibatan EBV terhadap outcome klinis pasien namun nilai prognostik dari ekspresi LMP1 terhadap overall survival pasien DLBCL terkait EBV masih belum dapat dijelaskan.
Metode: Penelitian dengan desain cross sectional ini melibatkan 50 pasien DLBCL yang didiagnosis antara Januari 2017 sampai Juni 2018. Pengamatan dilakukan selama 60 bulan. Data yang dikumpulkan meliputi usia, gejala B, stadium tumor, subtipe molekuler, dan survival 5 tahun. Analisis data menggunakan uji beda dan kurva Kaplan-Meier.
Hasil: Dari 50 pasien, sebagian besar berusia diatas 40 tahun (88%), jenis kelamin laki-laki (60%), subtipe non GCB (62%), mengeluhkan semua gejala B (30%) dan stadium I (38%). Sebanyak 21 pasien meninggal (42%). Pasien dengan skor LMP1 yang tinggi menunjukkan overall survival yang lebih buruk secara bermakna dibandingkan dengan skor LMP1 yang rendah (P <0.001).
Kesimpulan: DLBCL yang mengekspresikan LMP1 berhubungan dengan rendahnya overall survival 5 tahun dibandingkan dengan yang tidak mengekspresikan LMP1.
Keywords
Full Text:
PDFReferences
Reksodiputro AH. Multicentre epi-demiology and survival study of b cell non hodgkin lymphoma patients in indonesia. J Blood Disorders TransfI. 2015 Mar; 6(2):1-5.
Gao X, Li J, Wang Y, Liu S, Yue B. Clinical characteristics and prognostic significance of eber positivity in diffuse large b-cell lymphoma: a meta-analysis. PLOS ONE. 2018 Jun; 13(6):1-13.
Keane C, Tobin J, Gunawardana J, Francis S, Gifford G, Gabrielli S, et al. The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. Eur J Haematol. 2019 Jun;103: 200-7.
Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. Ebv-positive diffuse large b-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 Apr;93: 953–962.
Gascoyne RD, Campo E, Jaffe ES, Chan WC, Chan JKC, Rosenwald A, et al. Diffuse large b-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. Who classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC. 2017.p.291-7.
Chen YP, Zhang WN, Chen L, Tang LL, Mao YP, Li WF, et al. Effect of latent membrane protein 1 expression on overall survival in epstein-barr virus-associated cancers: a literature-based meta-analysis. Oncotarget. 2015 Aug;6(30):29311-23.
Wang LW, Jiang S, Gewurz BE. Epstein-barr virus lmp1-mediated oncogenicity. J Virol. 2017 Aug; 91 (2):1-11.
Rutherford SC dan Leonard JP. DLBCL cell of origin: what role should it play in care today?. Oncology. 2018 Sep; 32 (9):445-9.
Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008 Sep; 27 (41):5497-510.
Wu X, Wang F, Li Y, Wang X, Liu P, Zhang H, et al. Evaluation of latent membrane protein 1 and micro RNA‑155 for the prognostic prediction of diffuse large B cell lymphoma. Oncology Letters. 2018 Mar; 15:9725-34.
Li XM, Xiao WH, Zhao HX. Prognostic significance of latent membrane protein 1 expression in non-Hodgkin lym- phoma a meta-analysis. Medicine. 2017 Mar;96:1-7.
Yodi AN, Indrawati (2016). Hubungan prevalensi subtipe molekuler abc/gcb dengan karakteristik klinis pasien diffuse large b-cell lymphoma di rsup sardjito tahun 2012-2014. Available from:http//etd.repository.ugm.ac.id/ home/detail_pencarian/96024.
Howlader N, Mariotto AB, Besson C, Suneja G, Robien K, Younes N, et al. Cancer-specific mortality, cure frac- tion, and noncancer causes of death among diffuse large b-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017 Feb;123(17):3326-34.
Sharma R, Cunningham D, Smith P, Robertson G, Dent O and Clarke SJ. Inflammatory (b) symptoms are independent predictors of myelo-suppression from chemotherapy in non-hodgkin lymphoma (nhl) patients– analysis of data from a british national lymphoma investigation phase iii trial comparing chop to pmitcebo. BMC Cancer. 2009 May;9(153):1-10
Yin X, Xu A, Fan F, Huang Z, Cheng Q, Zhang L, et al. Incidence and mortality trends and risk prediction nomogram for extranodal diffuse large b-cell lymphoma: an analysis of the surveillance, epidemiology, and end re- sults database. Front. Oncol.2019 Nov;9(1198):1-18.
Article Metrics
Abstract view : 292 timesPDF - 58 times
DOI: https://doi.org/10.26714/medart.4.1.2022.18-25
Refbacks
- There are currently no refbacks.
Contact
Faculty of Medicine, Universitas Muhammadiyah Semarang
Jl. Kedungmundu Raya No. 18, Semarang, Indonesia
Email: [email protected]